Sandoz agrees to pay USD 400 million to settle US generic drug pricing claims by 43 states

Reuters2026/08/03 05:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sandoz Group AG reached a settlement framework to resolve remaining US state and territory claims in generic drug antitrust pricing litigation.
Deal covers 43 states and territories; USD 400 million payable over seven years starting 2027, subject to approvals; total about USD 450 million.
Separate indirect reseller class settlement set at USD 28.5 million, pending court approval; no admission of wrongdoing in either agreement.
Company expects no change to full-year 2026 guidance or mid-term outlook; provisions increased to reflect the settlements.
Only remaining US antitrust cases involve individual opt-out plaintiffs; Sandoz continues to contest those claims.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2375804_en) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sandoz agrees to pay USD 400 million to settle US generic drug pricing claims by 43 states

You may also like

Crypto prices